First-pass extracted concept

tissue and organ engineering

Candidate: concept label1 source documents5 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

regenerative medicine

Extracted Explainers

What the tool is doing

The paper discusses tissue and organ engineering as a regenerative medicine area aimed at replacing or regenerating human cells, tissues, or organs.

Source 1DOI PubMed

What problem it solves

It is framed as addressing restoration of natural function through replacement or regeneration of biological material.

Source 1DOI PubMed

Evidence Snippets

Regenerative medicine involves restoring natural function by replacing or regenerating human cells, tissues, or organs. Despite projections of significant market growth, venture capital (VC) investment in tissue and organ engineering has recently declined.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 5 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1associationsupports2026Source 1DOI PubMed

Prior exposure to regenerative medicine was significantly associated with future investment likelihood among surveyed VC investors.

Quoted textsource-backed

Prior exposure to regenerative medicine was significantly associated with future investment likelihood (p = 0.0464).

Claim 2correlationsupports2026Source 1DOI PubMed

Perceived investment potential in tissue and organ engineering strongly correlated with assets under management and investment stage.

Quoted textsource-backed

Investment potential strongly correlated with assets under management (ρ = 0.67) and investment stage (ρ = 0.66).

Claim 3qualitative findingsupports2026Source 1DOI PubMed

VC interest in tissue and organ engineering was shaped by prior investment experience, time horizon misalignment, clinical risk expectations, and market readiness.

Quoted textsource-backed

Interviews emphasized four factors shaping VC interest in tissue and organ engineering: prior investment experience, time horizon misalignment, clinical risk expectations, and market readiness.

Claim 4recommendationsupports2026Source 1DOI PubMed

Startups in tissue and organ engineering can improve investor appeal by targeting long-horizon investors, outlining clinical and regulatory pathways, and generating robust comparative evidence to support value-based reimbursement.

Quoted textsource-backed

Startups can improve appeal by targeting long-horizon investors, outlining clinical and regulatory pathways, and generating robust, comparative evidence to support value-based reimbursement.

Claim 5survey findingsupports2026Source 1DOI PubMed

Clinical validation and adoption were the most frequently cited major investment drivers among respondents, with reimbursement and regulatory challenges also identified.

Quoted textsource-backed

Among 20 respondents, clinical validation (n = 8) and adoption (n = 8) were most often cited as major investment drivers, followed by reimbursement and regulatory challenges.